Heart valve disease, etc.
Conditions
Interventions
Experimental group:Bayesian model administration
Control group:Conventional administration
Sponsors
Fujian Medical University Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Warfarin anticoagulant therapy is required for at least 3 months; 2. patients be able to take regular monitoring of INR and follow-up; 3. The patient or family members can understand the research plan and will participate in this study and provide a written informed consent
Exclusion criteria
Exclusion criteria: 1. Severe liver dysfunction (ChildPugh = 10); 2. Severe infection, respiratory failure; 3. Severe heart failure ( NYHA = IV); 4. Severe renal insufficiency (Ccr = 20ml / min); 5. Cancer; 6. Diseases of the blood system; 7. Severe pulmonary hypertension (PAPm = 45mmHg); 8. Abnormal thyroid function; 9. Patients with a history of venous thromboembolism, or serious events such as severe bleeding or embolism; 10. Women who are pregnant or breastfeeding; 11. Taking or planning to take other oral anticoagulants; 12. The base INR value is >1.4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time in therapeutic range;Excessive anticoagulation;Bleeding event;Thrombotic event; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time required to reach the target INR for the first time;;Time from treatment initiation to stable dose; | — |
Countries
China
Contacts
Public ContactJinhua Zhang
Fujian Medical University Union Hospital
Outcome results
None listed